Fedovapagon

Drug Profile

Fedovapagon

Alternative Names: VA-106483; VA483

Latest Information Update: 05 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vantia Therapeutics
  • Class Antidiuretics; Small molecules
  • Mechanism of Action Vasopressin V2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Nocturia

Most Recent Events

  • 03 Oct 2017 Vantia Therapeutics announces intention to submit NDA to US FDA and MAA to EMA for Nocturia
  • 03 Oct 2017 Positive top-line safety and efficacy data from the phase II/III trial in Nocturia released by (Vantia Therapeutics)
  • 03 Oct 2017 Vantia Therapeutics plans a second pivotal phase III trial for Nocturia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top